{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-023667","form_type":"8-K","ticker":"RAPH","cik":"0001415397","company_name":"Raphael Pharmaceutical Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.845449+00:00","generated_at":"2026-06-17T12:32:20.809697+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Israeli Ministry of Health approves Raphael Pharma's Phase IIa COVID-19 trial for cannabis-based drug","bullets":["Israeli Ministry of Health approved Raphael Pharmaceutical's application to commence a Phase IIa clinical trial in COVID-19 patients.","The trial protocol was approved by the Helsinki Committee at Rambam Hospital on December 8, 2022.","The trial involves a cannabis-based drug aimed at mitigating deterioration in COVID-19 patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-023667","json":"https://secwatch.observer/filing/0001213900-23-023667.json","markdown":"https://secwatch.observer/filing/0001213900-23-023667.md","text":"https://secwatch.observer/filing/0001213900-23-023667.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1415397/000121390023023667/0001213900-23-023667-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1415397/000121390023023667/ea175896-8k_raphael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T12:32:20.809697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}